[11C]A-69024: A potent and selective non-benzazepine radiotracer for in vivo studies of dopamine D1 receptors

Michael Kassiou, Ursula Scheffel, Hayden T. Ravert, William B Mathews, John L. Musachio, Richard M. Lambrecht, Robert F Dannals

Research output: Contribution to journalArticle

Abstract

[11C]A-69024, (±)-1-(2-bromo-4,5-dimethoxybenzyl)-7-hydroxy-6-methoxy-2-[1 1C]methyl-1,2,3,4-tetra-hydroisoquinoline, is a specific and selective dopamine D1 radiotracer. The in vivo biodistribution of this novel radioligand in mice showed a high uptake in the striatum (6.7%ID/g) at 5 min, followed by clearance with a half-life of 16.1 min. As a measure of specificity, the striatal/cerebellar ratio reached a maximum of 7.4 at 30 min post-injection. Radioactivity in the striatum was reduced to the level of the cerebellum by pre-adminstration of the D1 antagonist SCH 23390 (1 mg/kg). Pretreatment of mice with spiperone (D2), 7-hydroxydipropylaminotetralin (7-OH-DPAT) (D3), clozapine (D4), ketanserin (5-HT2/5-HT2C), mazindol (monoamine reuptake), prazosin (α1), and haloperidol (D2/σ) had no inhibitory effect on [11C]A-69024 uptake in the striatum. The dextrorotatory enantiomer of the dopamine antagonist butaclamol inhibited striatal uptake, while the less active isomer (-)-butaclamol did not. [11C]A-69024 binding was inhibited by unlabeled A-69024 in a dose dependent manner (ED50 = 0.3 mg/kg) in the striatum while no change occurred in the cerebellum. [11C]A-69024 warrants further investigation as a PET ligand for examination of central dopamine D1 receptors in humans.

Original languageEnglish (US)
Pages (from-to)221-226
Number of pages6
JournalNuclear Medicine and Biology
Volume22
Issue number2
DOIs
StatePublished - 1995

Fingerprint

A 69024
Dopamine D1 Receptors
Butaclamol
Corpus Striatum
Cerebellum
Mazindol
Spiperone
Ketanserin
Dopamine Antagonists
Clozapine
Prazosin
Haloperidol
Radioactivity
Half-Life
Dopamine
Ligands
Injections

ASJC Scopus subject areas

  • Cancer Research
  • Molecular Medicine
  • Radiology Nuclear Medicine and imaging

Cite this

[11C]A-69024 : A potent and selective non-benzazepine radiotracer for in vivo studies of dopamine D1 receptors. / Kassiou, Michael; Scheffel, Ursula; Ravert, Hayden T.; Mathews, William B; Musachio, John L.; Lambrecht, Richard M.; Dannals, Robert F.

In: Nuclear Medicine and Biology, Vol. 22, No. 2, 1995, p. 221-226.

Research output: Contribution to journalArticle

Kassiou, Michael ; Scheffel, Ursula ; Ravert, Hayden T. ; Mathews, William B ; Musachio, John L. ; Lambrecht, Richard M. ; Dannals, Robert F. / [11C]A-69024 : A potent and selective non-benzazepine radiotracer for in vivo studies of dopamine D1 receptors. In: Nuclear Medicine and Biology. 1995 ; Vol. 22, No. 2. pp. 221-226.
@article{c614c381cb5047b797ce947efea11df7,
title = "[11C]A-69024: A potent and selective non-benzazepine radiotracer for in vivo studies of dopamine D1 receptors",
abstract = "[11C]A-69024, (±)-1-(2-bromo-4,5-dimethoxybenzyl)-7-hydroxy-6-methoxy-2-[1 1C]methyl-1,2,3,4-tetra-hydroisoquinoline, is a specific and selective dopamine D1 radiotracer. The in vivo biodistribution of this novel radioligand in mice showed a high uptake in the striatum (6.7{\%}ID/g) at 5 min, followed by clearance with a half-life of 16.1 min. As a measure of specificity, the striatal/cerebellar ratio reached a maximum of 7.4 at 30 min post-injection. Radioactivity in the striatum was reduced to the level of the cerebellum by pre-adminstration of the D1 antagonist SCH 23390 (1 mg/kg). Pretreatment of mice with spiperone (D2), 7-hydroxydipropylaminotetralin (7-OH-DPAT) (D3), clozapine (D4), ketanserin (5-HT2/5-HT2C), mazindol (monoamine reuptake), prazosin (α1), and haloperidol (D2/σ) had no inhibitory effect on [11C]A-69024 uptake in the striatum. The dextrorotatory enantiomer of the dopamine antagonist butaclamol inhibited striatal uptake, while the less active isomer (-)-butaclamol did not. [11C]A-69024 binding was inhibited by unlabeled A-69024 in a dose dependent manner (ED50 = 0.3 mg/kg) in the striatum while no change occurred in the cerebellum. [11C]A-69024 warrants further investigation as a PET ligand for examination of central dopamine D1 receptors in humans.",
author = "Michael Kassiou and Ursula Scheffel and Ravert, {Hayden T.} and Mathews, {William B} and Musachio, {John L.} and Lambrecht, {Richard M.} and Dannals, {Robert F}",
year = "1995",
doi = "10.1016/0969-8051(94)00086-Y",
language = "English (US)",
volume = "22",
pages = "221--226",
journal = "Nuclear Medicine and Biology",
issn = "0969-8051",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - [11C]A-69024

T2 - A potent and selective non-benzazepine radiotracer for in vivo studies of dopamine D1 receptors

AU - Kassiou, Michael

AU - Scheffel, Ursula

AU - Ravert, Hayden T.

AU - Mathews, William B

AU - Musachio, John L.

AU - Lambrecht, Richard M.

AU - Dannals, Robert F

PY - 1995

Y1 - 1995

N2 - [11C]A-69024, (±)-1-(2-bromo-4,5-dimethoxybenzyl)-7-hydroxy-6-methoxy-2-[1 1C]methyl-1,2,3,4-tetra-hydroisoquinoline, is a specific and selective dopamine D1 radiotracer. The in vivo biodistribution of this novel radioligand in mice showed a high uptake in the striatum (6.7%ID/g) at 5 min, followed by clearance with a half-life of 16.1 min. As a measure of specificity, the striatal/cerebellar ratio reached a maximum of 7.4 at 30 min post-injection. Radioactivity in the striatum was reduced to the level of the cerebellum by pre-adminstration of the D1 antagonist SCH 23390 (1 mg/kg). Pretreatment of mice with spiperone (D2), 7-hydroxydipropylaminotetralin (7-OH-DPAT) (D3), clozapine (D4), ketanserin (5-HT2/5-HT2C), mazindol (monoamine reuptake), prazosin (α1), and haloperidol (D2/σ) had no inhibitory effect on [11C]A-69024 uptake in the striatum. The dextrorotatory enantiomer of the dopamine antagonist butaclamol inhibited striatal uptake, while the less active isomer (-)-butaclamol did not. [11C]A-69024 binding was inhibited by unlabeled A-69024 in a dose dependent manner (ED50 = 0.3 mg/kg) in the striatum while no change occurred in the cerebellum. [11C]A-69024 warrants further investigation as a PET ligand for examination of central dopamine D1 receptors in humans.

AB - [11C]A-69024, (±)-1-(2-bromo-4,5-dimethoxybenzyl)-7-hydroxy-6-methoxy-2-[1 1C]methyl-1,2,3,4-tetra-hydroisoquinoline, is a specific and selective dopamine D1 radiotracer. The in vivo biodistribution of this novel radioligand in mice showed a high uptake in the striatum (6.7%ID/g) at 5 min, followed by clearance with a half-life of 16.1 min. As a measure of specificity, the striatal/cerebellar ratio reached a maximum of 7.4 at 30 min post-injection. Radioactivity in the striatum was reduced to the level of the cerebellum by pre-adminstration of the D1 antagonist SCH 23390 (1 mg/kg). Pretreatment of mice with spiperone (D2), 7-hydroxydipropylaminotetralin (7-OH-DPAT) (D3), clozapine (D4), ketanserin (5-HT2/5-HT2C), mazindol (monoamine reuptake), prazosin (α1), and haloperidol (D2/σ) had no inhibitory effect on [11C]A-69024 uptake in the striatum. The dextrorotatory enantiomer of the dopamine antagonist butaclamol inhibited striatal uptake, while the less active isomer (-)-butaclamol did not. [11C]A-69024 binding was inhibited by unlabeled A-69024 in a dose dependent manner (ED50 = 0.3 mg/kg) in the striatum while no change occurred in the cerebellum. [11C]A-69024 warrants further investigation as a PET ligand for examination of central dopamine D1 receptors in humans.

UR - http://www.scopus.com/inward/record.url?scp=0028986392&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028986392&partnerID=8YFLogxK

U2 - 10.1016/0969-8051(94)00086-Y

DO - 10.1016/0969-8051(94)00086-Y

M3 - Article

C2 - 7767316

AN - SCOPUS:0028986392

VL - 22

SP - 221

EP - 226

JO - Nuclear Medicine and Biology

JF - Nuclear Medicine and Biology

SN - 0969-8051

IS - 2

ER -